CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH The trial involved 317 patients with CLL or SLL, including 247 who previously received BTK inhibitor treatment.
The recently concluded phase 1-2 trial of pirtobrutinib, a highly selective, noncovalent BTK inhibitor, offers promising new hope for patients with relapsed or refractory B-cell cancers such as chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) previously treated with covalent BTK inhibitors.
Key Points:
- Median number of prior therapy lines for these 247 patients was three.
- Overall response rate to pirtobrutinib was 73.3% and increased to 82.2% when including partial responses with lymphocytosis.
- Median progression-free survival was 19.6 months.
Additional Points:
- Among the 247 patients, 40.5% had received a BCL2 inhibitor such as venetoclax.
- The most common adverse events among all patients were infections (71.0%), bleeding (42.6%), and neutropenia (32.5%).
- Adverse events typical of BTK inhibitors, including hypertension, atrial fibrillation, and major hemorrhage, were infrequent, and only 2.8% of patients discontinued pirtobrutinib due to treatment-related adverse events.
Conclusion:
- Pirtobrutinib demonstrated efficacy in heavily pretreated CLL or SLL patients who had received a covalent BTK inhibitor, with a manageable side-effect profile.
Hematology/Oncology Latest Posts
- Major Lawsuit Against Cancer Charity Offers Reminder to Oncologists
- Oncology Fraud: Authorities Now Better Able to Detect Billing Abuses
- Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis
- Oncology Leader Calls for Antitrust Probe: “We’re Talking About People’s Lives”
Did You Know?
As of 2021, chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults, accounting for about one-third of all leukemia cases in the United States.
